All Stories

  1. Real‐world profiles and associated factors of pediatric asthma monitoring
  2. Reply: Core outcome sets for pneumonia: the beginning, not the end
  3. A conceptual framework for addressing treatment withdrawal effects across the evidence pathway
  4. From airways to arteries: cardiovascular and kidney risk in chronic obstructive pulmonary disease
  5. Withdrawal effects following treatment discontinuation: A blind spot in evidence-based medicine
  6. Inhaled corticosteroids and risk of cardiovascular events in chronic obstructive pulmonary disease: a nationwide cohort study in Denmark
  7. COPD Trial Evidence Comes from a Narrow Slice of the World: A Population Representativeness Analysis.
  8. Editorial: Biologics for airway diseases: from bench to bedside
  9. ERS International congress 2025: highlights from the airway diseases assembly
  10. Prevalence of respiratory viruses in stable and acute asthma: a systematic review and meta-analysis
  11. New GRADE Evidence-to-Decision Framework for Pairwise and Multiple Comparisons (GRADE Guidance 45)
  12. The Hidden Penalty for UK Clinical Academics: An Overlooked Inequity in Consultant Pay Progression
  13. COPD and kidney disease: not so far apart?
  14. GRADE Guidance: Update on Developing Good Practice Statements in Guidelines
  15. Plasma growth differentiation factor-15 is associated with cardiovascular events in patients hospitalized for acute exacerbation of COPD
  16. Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
  17. Disproportionate increase in COPD exacerbation risk for 3 months after discontinuing LAMA or ICS: insights from the FLAME trial
  18. Molnupiravir or nirmatrelvir–ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
  19. The silent exclusion: rethinking eligibility and generalizability in clinical trials
  20. Chronic Obstructive Pulmonary Disease (COPD): Developments in Pharmacological Treatments
  21. Reduced treatment response to inhaled corticosteroids in current smokers with COPD, regardless of blood eosinophil count: insights from the FLAME trial
  22. Beyond survival: improving lung cancer rehabilitation through standardised outcomes
  23. Characterising acute and chronic care needs: insights from the Global Burden of Disease Study 2019
  24. Decoding community-acquired pneumonia: a systematic review and analysis of diagnostic criteria and definitions used in clinical trials
  25. Global, regional, and national burden of household air pollution, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
  26. Global, regional, and national burden of asthma and atopic dermatitis, 1990–2021, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021
  27. Predictors of treatment REsponse to inhaled corticosteroids (ICS) in Chronic Obstructive pulmonary disease: randomised controlled trials individual participant Data re-Evaluation–protocol of the ICS-RECODE individual participant data meta-analysis
  28. Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial
  29. ERS Congress 2024: highlights from the Airway Diseases Assembly
  30. Prevalence of Respiratory Viruses in Stable and Acute Asthma: A Systematic Review and Meta-Analysis
  31. Patient-centred composite scores as tools for assessment of response to biological therapy for paediatric and adult severe asthma
  32. Rethinking Blood Eosinophils for Assessing Inhaled Corticosteroids Response in COPD
  33. Steroids in severe community-acquired pneumonia
  34. GRADE guidance 39: using GRADE-ADOLOPMENT to adopt, adapt or create contextualized recommendations from source guidelines and evidence syntheses
  35. Effect of low climate impact vs. high climate impact inhalers for patients with asthma and COPD-a nationwide cohort analysis
  36. Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050
  37. Inhaled Corticosteroids Particle Size and Risk of Hospitalization Due to Exacerbations and All-Cause Mortality in Patients with Chronic Obstructive Pulmonary Disease. A Nationwide Cohort Study
  38. European Respiratory Society guidelines for the Diagnosis and Management of Pulmonary Alveolar Proteinosis
  39. AM/PM dosing of LAMA for COPD: a randomized controlled trial protocol using digital recruitment and registries
  40. Unravelling the complexity of ventilator-associated pneumonia: a systematic methodological literature review of diagnostic criteria and definitions used in clinical research
  41. The state of health in the European Union (EU-27) in 2019: a systematic analysis for the Global Burden of Disease study 2019
  42. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
  43. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a syst...
  44. Burden of disease scenarios for 204 countries
  45. Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
  46. Current options in the management of tree nut allergy: A systematic review and narrative synthesis
  47. Recommendations for asthma monitoring in children: A PeARL document endorsed by APAPARI, EAACI, INTERASMA, REG, and WAO
  48. Global, regional, and national incidence and mortality burden of non-COVID-19 lower respiratory infections and aetiologies, 1990–2021: a systematic analysis from the Global Burden of Disease Study 2021
  49. Immunomodulatory drugs in sepsis: a systematic review and meta‐analysis
  50. Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial
  51. Global Health Trends 1950–2021: Impact of COVID-19 on Mortality and Population Growth
  52. Reply to “The use of basophil activation tests (BATs) in the diagnosis of penicillin allergy”
  53. Performance Characteristics of Basophil Activation Tests for Diagnosing Penicillin Allergy: A Meta-Analysis
  54. Prognostic factors for mortality, ICU, MIS-C and hospital admission due to SARS-CoV-2 in paediatric patients: A systematic review and meta-analysis
  55. Inhaledversussystemic corticosteroids for acute exacerbations of COPD: a systematic review and meta-analysis
  56. The Fagerström Test for Nicotine Dependence, as a prognostic factor, in current smokers with and without COPD: A cross-sectional study in northern Greece
  57. Covariates in population pharmacokinetic studies of critically ill adults receiving β-lactam antimicrobials: a systematic review and narrative synthesis
  58. Clinical trials of pneumonia management assess heterogeneous outcomes and measurement instruments
  59. ERS International Congress 2023: highlights from the Airway Diseases Assembly
  60. Prevalence and clinical implications of respiratory viruses in asthma during stable disease state and acute attacks: Protocol for a meta-analysis
  61. Promising treatment biomarkers in asthma
  62. Rethinking Blood Eosinophils for Assessing ICS Response in COPD: A Post-Hoc Analysis from FLAME
  63. Global, regional, and national incidence of six major immune-mediated inflammatory diseases: findings from the global burden of disease study 2019
  64. Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
  65. Impact of self-reported environmental mould exposure on COPD outcomes
  66. Population pharmacokinetics critically ill beta lactam (ClinicalTrials.gov).
  67. Population pharmacokinetics critically ill beta lactam (Cochrane, CENTRAL).
  68. Population pharmacokinetics critically ill beta lactam (Embase, Ovid).
  69. Population pharmacokinetics critically ill beta lactam (MEDLINE (R) All, Ovid).
  70. Population pharmacokinetics critically ill beta lactam (Web of Science).
  71. The unfinished agenda of communicable diseases among children and adolescents before the COVID-19 pandemic, 1990–2019: a systematic analysis of the Global Burden of Disease Study 2019
  72. Combined Pulmonary Fibrosis and Emphysema: Comparative Evidence on a Complex Condition
  73. Current and future developments in the pharmacology of asthma and COPD: ERS seminar, Naples 2022
  74. Current and Optimal Practices in Childhood Asthma Monitoring Among Multiple International Stakeholders
  75. ERS International Congress 2022: highlights from the Airway Diseases Assembly
  76. Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial
  77. Core outcome sets, developed collaboratively with patients, can improve the relevance and comparability of clinical trials
  78. Monocyte migration profiles define disease severity in acute COVID-19 and unique features of long COVID
  79. Inhaled Corticosteroids in Patients with Chronic Obstructive Pulmonary Disease and Risk of Acquiring Streptococcus pneumoniae Infection. A Multiregional Epidemiological Study
  80. Impact of triple therapy on mortality in COPD
  81. Mucolytics for acute exacerbations of chronic obstructive pulmonary disease: a meta-analysis
  82. The clinical spectrum of aspergillosis in chronic obstructive pulmonary disease
  83. Predictors and associations of the persistent airflow limitation phenotype in asthma: a post-hoc analysis of the ATLANTIS study
  84. How to peer review: practical advice for early career researchers
  85. Prognostic factors for mortality, intensive care unit and hospital admission due to SARS-CoV-2: a systematic review and meta-analysis of cohort studies in Europe
  86. Age–sex differences in the global burden of lower respiratory infections and risk factors, 1990–2019: results from the Global Burden of Disease Study 2019
  87. The burden of bacterial antimicrobial resistance in the WHO European region in 2019: a cross-country systematic analysis
  88. GRADE guidance 35: update on rating imprecision for assessing contextualized certainty of evidence and making decisions
  89. West Nile Disease Symptoms and Comorbidities: A Systematic Review and Analysis of Cases
  90. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
  91. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
  92. Biomarkers of Clot Activation and Degradation and Risk of Future Major Cardiovascular Events in Acute Exacerbation of COPD: A Cohort Sub-Study in a Randomized Trial Population
  93. Peripheral neuropathy: A neglected cause of disability in COPD – A narrative review
  94. Presence of antiphospholipid antibodies is associated with increased implantation failure following in vitro fertilization technique and embryo transfer: A systematic review and meta-analysis
  95. Structural epitope profiling identifies antibodies associated with critical COVID-19 and long COVID
  96. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis
  97. Transmission of SARS-CoV-2 in educational settings in 2020: a review
  98. Prognostic factors for mortality, ICU and hospital admission due to SARS-CoV-2: A systematic review and meta-analysis of cohort studies in Europe
  99. Inspiring stories: the impact that being part of ERS activities can have on a professional career
  100. Burden of non-communicable diseases among adolescents aged 10–24 years in the EU, 1990–2019: a systematic analysis of the Global Burden of Diseases Study 2019
  101. Outcomes assessed in therapeutic randomized controlled trials in hospitalized patients with COVID-19: is the meta Core Outcome Set (meta-COS) adopted?
  102. Adrenal suppression in patients with chronic obstructive pulmonary disease treated with glucocorticoids: Role of specific glucocorticoid receptor polymorphisms
  103. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
  104. Intermittent prophylactic antibiotics for bronchiectasis
  105. Assessing Treatment Success or Failure as an Outcome in Randomised Clinical Trials of COPD Exacerbations. A Meta-Epidemiological Study
  106. Management of COVID-19-Associated Acute Respiratory Failure with Alternatives to Invasive Mechanical Ventilation: High-Flow Oxygen, Continuous Positive Airway Pressure, and Noninvasive Ventilation
  107. Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
  108. Inhaled Phosphodiesterase Inhibitors for the Treatment of Chronic Obstructive Pulmonary Disease
  109. Chronic obstructive pulmonary disease and COVID-19: interrelationships
  110. The role of educational settings in the transmission chain of SARS-CoV-2 in 2020: a systematic review
  111. ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
  112. Automated lung sound analysis using the LungPass platform: a sensitive and specific tool for identifying lower respiratory tract involvement in COVID-19
  113. ERS/EAACI statement on adherence to international adult asthma guidelines
  114. Stigma: an unmet public health priority in COPD
  115. Automated lung sound analysis using the LungPass platform: A sensitive and specific tool for identifying lower respiratory tract involvement in COVID-19
  116. Management of asthma in childhood: study protocol of a systematic evidence update by the Paediatric Asthma in Real Life (PeARL) Think Tank
  117. Corticosteroid Resistance in Smokers—A Substudy Analysis of the CORTICO-COP Randomised Controlled Trial
  118. ERS clinical practice guidelines on treatment of sarcoidosis
  119. Screening, Diagnostic and Prognostic Tests for COVID-19: A Comprehensive Review
  120. The association between beta-blocker therapy and daytime sleepiness in obstructive sleep apnoea
  121. Multidimensional indices in the assessment of chronic obstructive pulmonary disease
  122. Alterations in T and B cell function persist in convalescent COVID-19 patients
  123. Effect of different corticosteroid regimes for hospitalised patients with exacerbated COPD: pooled analysis of individual participant data from the REDUCE and CORTICO-COP trials
  124. Triglyceride-Glucose Index in Non-Diabetic, Non-Obese Patients with Obstructive Sleep Apnoea
  125. Childhood asthma outcomes during the COVID‐19 pandemic: Findings from the PeARL multi‐national cohort
  126. Self-Reported Real-World Safety and Reactogenicity of COVID-19 Vaccines: A Vaccine Recipient Survey
  127. Self-reported real-world safety and reactogenicity of COVID-19 vaccines: An international vaccine-recipient survey
  128. P190 Systematic survey of reported outcomes in ventilator associated pneumonia randomised controlled trials
  129. Prophylactic antibiotics for adults with chronic obstructive pulmonary disease: a network meta-analysis
  130. GRADE Guidelines 30: the GRADE approach to assessing the certainty of modeled evidence—An overview in the context of health decision-making
  131. Developing trustworthy recommendations as part of an urgent response (1–2 weeks): a GRADE concept paper
  132. Polymorphisms of the Glucocorticoid Receptor Gene and Adrenal Suppression in Patients with Chronic Obstructive Pulmonary Disease Treated with Glucocorticoids for Acute Exacerbations
  133. Outcomes Evaluated in Controlled Clinical Trials on the Management of COVID-19: A Methodological Systematic Review
  134. Current developments and future directions in COPD
  135. COVID-19 and COPD: a narrative review of the basic science and clinical outcomes
  136. Childhood asthma outcomes during the COVID-19 pandemic: Findings from the PeARL multi-national cohort
  137. Outcomes evaluated in controlled clinical trials on the management of COVID-19: A methodological systematic review
  138. Recovery of monocyte exhaustion is associated with resolution of lung injury in COVID-19 convalescence
  139. Bone turnover biomarkers in COPD patients randomized to either a regular or shortened course of corticosteroids: a substudy of the randomized controlled CORTICO-COP trial
  140. Longitudinal immune profiling reveals key myeloid signatures associated with COVID-19
  141. Impact of COVID-19 on Pediatric Asthma: Practice Adjustments and Disease Burden
  142. Long-Acting Bronchodilators for Chronic Obstructive Pulmonary Disease
  143. Severity-stratified and longitudinal analysis of VWF/ADAMTS13 imbalance, altered fibrin crosslinking and inhibition of fibrinolysis as contributors to COVID-19 coagulopathy
  144. Comparison of the Level of Awareness about the Transmission of Echinococcosis and Toxocariasis between Pet Owners and Non-Pet Owners in Greece
  145. Problems arising from the conduct of multiple trials evaluating the same interventions for COVID-19
  146. The DisEntangling Chronic Obstructive pulmonary Disease Exacerbations clinical trials NETwork (DECODE-NET): rationale and vision
  147. Core outcome set for the management of acute exacerbations of chronic obstructive pulmonary disease: the COS-AECOPD ERS Task Force study protocol
  148. Longitudinal immune profiling reveals distinct features of COVID-19 pathogenesis
  149. Research Priorities in Pediatric Asthma: Results of a Global Survey of Multiple Stakeholder Groups by the Pediatric Asthma in Real Life (PeARL) Think Tank
  150. Prevalence and clinical implications of respiratory viruses in stable chronic obstructive pulmonary disease (COPD) and exacerbations: a systematic review and meta-analysis protocol
  151. Acute exacerbations of chronic obstructive pulmonary disease: in search of diagnostic biomarkers and treatable traits
  152. Change in blood eosinophils following treatment with inhaled corticosteroids may predict long-term clinical response in COPD
  153. The need for clean air: The way air pollution and climate change affect allergic rhinitis and asthma
  154. ERS International Congress, Madrid, 2019: highlights from the Airway Diseases, Asthma and COPD Assembly
  155. Corrigendum to: Transfusion-Transmitted Malaria: A Systematic Review and Meta-Analysis
  156. Long-Lasting Alterations in T and B Cell Function in Convalescent COVID-19 Patients
  157. A systematic evaluation of the diagnostic criteria for COPD and exacerbations used in randomised controlled trials on the management of COPD exacerbations
  158. Laboratory Cross-Contamination of Mycobacterium tuberculosis: A Systematic Review and Meta-analysis
  159. Transfusion-Transmitted Malaria: A Systematic Review and Meta-analysis
  160. How do clinical trials on COPD exacerbations evaluate the effect treatments have on patients?
  161. Was the implementation strategy of the ProACT trial adequately proactive?
  162. Chronic Airway Diseases Early Stratification (CADSET): a new ERS Clinical Research Collaboration
  163. Systematic review on women's values and preferences concerning breast cancer screening and diagnostic services
  164. Research highlights from the 2018 European Respiratory Society International Congress: airway disease
  165. Intermittent prophylactic antibiotics for bronchiectasis
  166. What is the impact of GOLD 2017 recommendations in primary care? – a descriptive study of patient classifications, treatment burden and costs [Erratum]
  167. Prophylactic antibiotics for adults with chronic obstructive pulmonary disease: a network meta-analysis
  168. Biomarkers to guide antibiotic therapy for COPD exacerbations
  169. Capsule Commentary on Ashburner et al., Electronic Physician Notifications to Improve Guideline-Based Anticoagulation in Atrial Fibrillation: a Randomized Controlled Trial
  170. What is the impact of GOLD 2017 recommendations in primary care? – a descriptive study of patient classifications, treatment burden and costs
  171. EARLY versus MILD Chronic Obstructive Pulmonary Disease (COPD)
  172. Continuous versus intermittent antibiotics for bronchiectasis
  173. COPD and Stroke
  174. The emerging Chinese COPD epidemic
  175. Capsule Commentary on Bremmer et. al., Impact of Procalcitonin Guidance on Management of Adults Hospitalized with Chronic Obstructive Pulmonary Disease Exacerbations
  176. Research highlights from the 2017 ERS International Congress: airway diseases in focus
  177. Early Career Members at the ERS International Congress 2017: highlights from the Assemblies
  178. Efficacy and safety of tiotropium and olodaterol in COPD: a systematic review and meta-analysis
  179. Airways diseases: insights from the European Respiratory Society Annual Congress 2017
  180. ERS Early Career Members meet EAACI Junior Members: the launch of a strong, fruitful collaboration
  181. Continuous versus intermittent antibiotics for non-cystic fibrosis bronchiectasis
  182. GRADE guidelines 17: assessing the risk of bias associated with missing participant outcome data in a body of evidence
  183. Interventions to improve inhaler technique and adherence to inhaled corticosteroids in children with asthma
  184. Opportunities for early career members
  185. Relationship of Allergy with Asthma: There Are More Than the Allergy “Eggs” in the Asthma “Basket”
  186. Tinzaparin for Long-Term Treatment of Venous Thromboembolism in Patients With Cancer: A Systematic Review and Meta-Analysis
  187. Interventions to improve inhaler technique for people with asthma
  188. Procalcitonin to guide antibiotic administration in COPD exacerbations: a meta-analysis
  189. Early Career Members at the ERS International Congress London 2016
  190. How to keep good clinical records
  191. Prevalence and burden of comorbidities in COPD
  192. Valvular-CHADS-VASc as a safer alternative to CHADS-VASc score
  193. Serum procalcitonin can guide antibiotic administration for respiratory tract infections in primary care
  194. Obstructive Sleep Apnea and Hypertension: A Bidirectional Causal Relation
  195. Overlap Syndrome of Chronic Obstructive Pulmonary Disease and Obstructive Sleep Apnoea
  196. The risk of tachyarrhythmias in patients with moderate-to-severe chronic kidney disease receiving tiotropium bromide
  197. Comparison of tumor markers and inflammatory biomarkers in chronic obstructive pulmonary disease (COPD) exacerbations
  198. Comparative mortality risk of tiotropium administered via handihaler or respimat in COPD patients: Are they equivalent?
  199. COPD Phenotypes and Biomarkers: Introducing Personalised Medicine
  200. Management of Stable COPD: An Update
  201. Editorial from Guest Editor (Thematic Issue: Current Approach to COPD Management: Setting a Model in Medical Therapeutics)
  202. Tiotropium HandiHaler Improves the Survival of Patients with COPD: A Systematic Review and Meta-Analysis
  203. Drugs that Act on the Respiratory Tract
  204. Expression of Bmi1, FoxF1, Nanog, and γ-Catenin in Relation to Hedgehog Signaling Pathway in Human Non-small-Cell Lung Cancer
  205. Tiotropium Inhaler Devices: Seeking Convenience When Mortality Is at Stake?
  206. Impact of long‐term treatment with low‐dose inhaled corticosteroids on the bone mineral density of chronic obstructive pulmonary disease patients: Aggravating or beneficial?
  207. Chronic bronchitis: an objective diagnosis of exclusion